NZ509244A - Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine, and/or phenylacetate - Google Patents

Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine, and/or phenylacetate

Info

Publication number
NZ509244A
NZ509244A NZ509244A NZ50924499A NZ509244A NZ 509244 A NZ509244 A NZ 509244A NZ 509244 A NZ509244 A NZ 509244A NZ 50924499 A NZ50924499 A NZ 50924499A NZ 509244 A NZ509244 A NZ 509244A
Authority
NZ
New Zealand
Prior art keywords
phenylacetylisoglutamine
phenylacetylglutamine
phenylacetate
administration
treatment regimen
Prior art date
Application number
NZ509244A
Other languages
English (en)
Inventor
Stainslaw R Burzynski
Original Assignee
Stanislaw R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanislaw R filed Critical Stanislaw R
Publication of NZ509244A publication Critical patent/NZ509244A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
NZ509244A 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine, and/or phenylacetate NZ509244A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
PCT/US1999/015017 WO2000004894A2 (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Publications (1)

Publication Number Publication Date
NZ509244A true NZ509244A (en) 2004-02-27

Family

ID=22397538

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ509244A NZ509244A (en) 1998-07-23 1999-07-02 Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine, and/or phenylacetate

Country Status (20)

Country Link
US (2) US6258849B1 (enExample)
EP (1) EP1098643B1 (enExample)
JP (2) JP2002521329A (enExample)
KR (4) KR100414587B1 (enExample)
CN (3) CN1605334A (enExample)
AT (1) ATE257378T1 (enExample)
AU (1) AU759278B2 (enExample)
BR (1) BR9912356A (enExample)
CA (1) CA2336945C (enExample)
DE (1) DE69914084T2 (enExample)
DK (1) DK1098643T3 (enExample)
EA (1) EA004179B1 (enExample)
ES (1) ES2214866T3 (enExample)
ID (1) ID28160A (enExample)
IL (1) IL140848A (enExample)
NZ (1) NZ509244A (enExample)
PL (1) PL213698B1 (enExample)
PT (1) PT1098643E (enExample)
WO (1) WO2000004894A2 (enExample)
ZA (1) ZA200100622B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
ATE311358T1 (de) * 2000-08-29 2005-12-15 Nobex Corp Immunoregulierende verbindungen, deren derivate und ihre verwendung
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
PL1773767T3 (pl) 2004-07-07 2016-07-29 Biocon Ltd Synteza azowo związanych związków immunoregulacyjnych
CA2575367A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
CN106810464B (zh) 2009-04-03 2019-01-22 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐及其制备方法
ES2517340T3 (es) 2009-06-08 2014-11-03 Ucl Business Plc Tratamiento de la hipertensión portal usando L-ornitina y fenilacetato
EP2625162B1 (en) 2010-10-06 2019-03-13 Ocera Therapeutics, Inc. Methods of making l-ornithine phenyl acetate
KR20230018526A (ko) 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
EP3397960B1 (en) * 2015-12-30 2020-01-29 Société des Produits Nestlé S.A. Method for determining fat free body mass
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
MX389665B (es) 2017-05-11 2025-03-20 Ocera Therapeutics Inc Procesos para producir fenilacetato de l-ornitina
EA202090024A1 (ru) * 2017-06-12 2020-04-10 Станислав Р. Бурзинский Способы лечения лептоменингеального заболевания
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
EP4731792A2 (en) * 2023-06-21 2026-04-29 Stanislaw R. Burzynski Compositions comprising antineoplastons and methods of treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5244922A (en) * 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
DE69734713T2 (de) 1996-05-14 2006-07-06 Burzynski, Stanislaw R., Houston Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität

Also Published As

Publication number Publication date
KR100417101B1 (ko) 2004-02-05
KR20010071025A (ko) 2001-07-28
EP1098643B1 (en) 2004-01-07
ZA200100622B (en) 2002-06-26
ID28160A (id) 2001-05-10
US6943192B2 (en) 2005-09-13
US20010044466A1 (en) 2001-11-22
EP1098643A2 (en) 2001-05-16
WO2000004894A3 (en) 2000-04-27
DK1098643T3 (da) 2004-05-24
KR20030027087A (ko) 2003-04-03
AU4854299A (en) 2000-02-14
PL213698B1 (pl) 2013-04-30
US6258849B1 (en) 2001-07-10
BR9912356A (pt) 2001-04-17
CN1605334A (zh) 2005-04-13
WO2000004894A2 (en) 2000-02-03
KR100417100B1 (ko) 2004-02-05
IL140848A0 (en) 2002-02-10
EA200100168A1 (ru) 2001-08-27
DE69914084D1 (de) 2004-02-12
KR20030027089A (ko) 2003-04-03
CA2336945A1 (en) 2000-02-03
CN1660061A (zh) 2005-08-31
CN1319010A (zh) 2001-10-24
CA2336945C (en) 2008-11-18
KR100399658B1 (ko) 2003-09-29
DE69914084T2 (de) 2004-10-28
EA004179B1 (ru) 2004-02-26
PT1098643E (pt) 2004-05-31
KR20030027088A (ko) 2003-04-03
JP2011051993A (ja) 2011-03-17
CN1191064C (zh) 2005-03-02
ATE257378T1 (de) 2004-01-15
PL345959A1 (en) 2002-01-14
ES2214866T3 (es) 2004-09-16
JP2002521329A (ja) 2002-07-16
AU759278B2 (en) 2003-04-10
CN100400039C (zh) 2008-07-09
IL140848A (en) 2005-05-17
HK1037142A1 (en) 2002-02-01
KR100414587B1 (ko) 2004-01-13

Similar Documents

Publication Publication Date Title
SE9504661D0 (sv) New compounds
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
TW568896B (en) Calcium receptor-active compounds
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
TR200002953T2 (tr) İki halkalı hidroksamik asit türevleri
ATE312080T1 (de) 2-chinolonen enthaltende arzneimittel
SE9401728D0 (sv) New compounds II
GEP20012390B (en) Benzonaphthyridines as Bronchial Therapeutics
EA200100168A1 (ru) Схема лечения при введении фенилацетилглутамина, фенилацетилизоглутамина и/или фенилацетата
IS2216B (is) Meðferðaráform við inngjöf á H+,K+ -ATPasa-hemla
MY118828A (en) Substituted amino compounds and their use as substances having an analgesic effect
FI960658A0 (fi) Uudet bis-naftalimidit syövän hoitamiseksi
DE60128100D1 (de) Analgetisches arzneimittel
SE9400447D0 (sv) New compounds
YU48915B (sh) Sulfonilkarbamid i postupak za njegovo dobijanje
KR910007531A (ko) 15-케토-프로스타글란딘 화합물을 이용한 간 담즙성 질병의 치료
SE9504662D0 (sv) New compounds
AU5390900A (en) Potassium channel blocking agents
CY1112050T1 (el) Νεα 2-αλογονοποιημενα παραγωγα της 5-0- δεσοσαμινυλερυθρονολιδης α, η διαδικασια της παρασκευης τους και η εφαρμογη τους ως φαρμακευτικα προϊοντα
NZ502366A (en) Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis
HUT54113A (en) Process for producing butenecarboxylic acid derivatives and pharmaceutical compositions comprising such compounds
EA200300516A1 (ru) Комбинация, включающая камптотецин и производные стильбена, для лечения рака
EP0784973A3 (en) Quinoxaline derivatives for treating tinnitus
ATE36957T1 (de) N,n-diethyl-5-methyl-2h,1-benzothiopyrano-(4,3, - cd)-indazol-2-ethanamine, diese enthaltende zubereitungen und ihre verwendung.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired